Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer H Foster

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Journal of the National Cancer Institute|March 26, 2026
FDA approvals for pediatric cancer indications using children's oncology group associated trials dataMargaret E Macy, Elizabeth Fox, Brenda J Weigel, et al.
Journal of Pediatric Surgery|July 20, 2021
Characteristics of benign neuroblastic tumors: Is surgery always necessary?Richard S Whitlock, Steven C Mehl, Sara K Larson, et al.
Pediatric Blood & Cancer|October 23, 2023
A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019Kevin Campbell, David A Siegel, Puja J Umaretiya, et al.
Cancer Chemotherapy and Pharmacology|November 30, 2018
A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicitiesJennifer H Foster, Patrick A Thompson, M Brooke Bernhardt, et al.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2024
Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)Jennifer H Foster, Joel M Reid, Charles Minard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)Jennifer H Foster, Stephan D Voss, David C Hall, et al.
Cancers|November 26, 2022
ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In VivoYang Yu, Yanling Zhao, Jongmin Choi, et al.
Pediatric Blood & Cancer|July 31, 2020
Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factorsSarah B Whittle, Valeria Smith, Allison Silverstein, et al.
JCO Clinical Cancer Informatics|April 10, 2026
Feasibility of Automated Laboratory Data Ascertainment and Transfer From Hospitals Into Medidata Rave Across Pediatric National Cancer Institute-Supported Cooperative GroupsTamara P Miller, Richard Aplenc, Charles Minard, et al.
The Journal of Pathology|June 4, 2021
Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhoodMichelle A Ting, Jacquelyn Reuther, Raghu Chandramohan, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Journal of the National Cancer Institute|March 26, 2026
FDA approvals for pediatric cancer indications using children's oncology group associated trials dataMargaret E Macy, Elizabeth Fox, Brenda J Weigel, et al.
Journal of Pediatric Surgery|July 20, 2021
Characteristics of benign neuroblastic tumors: Is surgery always necessary?Richard S Whitlock, Steven C Mehl, Sara K Larson, et al.
Pediatric Blood & Cancer|October 23, 2023
A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019Kevin Campbell, David A Siegel, Puja J Umaretiya, et al.
Cancer Chemotherapy and Pharmacology|November 30, 2018
A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicitiesJennifer H Foster, Patrick A Thompson, M Brooke Bernhardt, et al.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2024
Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)Jennifer H Foster, Joel M Reid, Charles Minard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)Jennifer H Foster, Stephan D Voss, David C Hall, et al.
Cancers|November 26, 2022
ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In VivoYang Yu, Yanling Zhao, Jongmin Choi, et al.
Pediatric Blood & Cancer|July 31, 2020
Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factorsSarah B Whittle, Valeria Smith, Allison Silverstein, et al.
JCO Clinical Cancer Informatics|April 10, 2026
Feasibility of Automated Laboratory Data Ascertainment and Transfer From Hospitals Into Medidata Rave Across Pediatric National Cancer Institute-Supported Cooperative GroupsTamara P Miller, Richard Aplenc, Charles Minard, et al.
The Journal of Pathology|June 4, 2021
Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhoodMichelle A Ting, Jacquelyn Reuther, Raghu Chandramohan, et al.
Pageof 6